End‐of‐life impact of concurrent diabetes mellitus and adrenal insufficiency as immune‐related adverse events in an advanced non‐small cell lung cancer patient
Abstract A 49‐year‐old man diagnosed with metastatic non‐small cell lung cancer was treated with immune checkpoint inhibitor (ICI) combination therapy (nivolumab + ipilimumab) as first‐line therapy. During the treatment course, the patient developed ICI‐associated diabetes mellitus and adrenal insuf...
Main Authors: | Tomoaki Nakamura, Yuki Takeyasu, Tatsuya Yoshida, Ken Ohashi, Yuichiro Ohe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-11-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14660 |
Similar Items
-
Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors
by: N.C. Helderman, et al.
Published: (2023-03-01) -
A Case of Nonsmall-Cell Lung Cancer with Anaphylaxis after 41 Courses of Pembrolizumab along with Adrenal Insufficiency as an Immune-Related Adverse Event
by: Tomoaki Nakamura, et al.
Published: (2022-09-01) -
Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
by: Kana Kurokawa, et al.
Published: (2023-02-01) -
Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
by: Masahiro Torasawa, et al.
Published: (2023-06-01) -
Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
by: Jing Xiang, et al.
Published: (2023-12-01)